Inspections, Compliance, Enforcement, and Criminal Investigations
www.secretsofbetterhealth.com dba My Cosmetic Company
Department of Health and Human Services
|Public Health Service
Food and Drug Administration
|Silver Spring, MD 20993-0002|
From: FDA Center for Drug Evaluation and Research
Date: December 1, 2009
To: www.secretsofbetterhealth.com / email@example.com
My Cosmetic Company
7 Coomoo Crescent, Mountain
Creek Queensland, 4557, Australia
Subject: Urgent Message from the Food and Drug Administration Regarding H1N1 Flu Virus-Related Products Marketed by Your Firm
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
SILVER SPRING, MD 20993
TO: www.secretsofbetterhealth.com / firstname.lastname@example.org
FROM: Food and Drug Administration
RE: Unapproved/Uncleared/Unauthorized Products Related to the H1N1 Flu Virus
DATE: December 1, 2009
This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.secretsofbetterhealth.com on October 26, 2009. The FDA has determined that your website offers a product for sale into the United States that is intended to diagnose, mitigate, prevent, treat, or cure the H1N1 Flu Virus in people. This product has not been approved, cleared, or otherwise authorized by FDA for use in the diagnosis, mitigation, prevention, treatment, or cure of the H1N1 Flu Virus. This product is Zeolite Internal Detox 250 gm. The marketing of this product for sale to customers in the United States violates the Federal Food, Drug, and Cosmetic Act (FFDC Act). 21 U.S.C. §§ 331, 351, 352. We request that you immediately cease marketing unapproved, uncleared, or unauthorized products for the diagnosis, mitigation, prevention, treatment, or cure of the H1N1 Flu Virus.
When viewed on October 26, 2009, the following claims appeared on your website:
• “Drink zeolite to neutralise and remove the toxins of Swine Flu”
• “Zeolite may afford considerable protection against the swine flu and other viruses.”
• “[C]oncentrations of 12, 25, and 50mg/ml of MZ induced a significant inhibitory effect
upon viral proliferation.”
Although these claims appear to have been taken down, the site continues to use metatags to bring consumers to your website description of Zeolite that include “swine flu,” “swine flu symptoms,” “swine flu treatment,” “H1N1,” and “pig flu.”
The Secretary of Health and Human Services, under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, has determined that a public health emergency exists nationwide involving the H1N1 Flu Virus that affects or has the significant potential to affect national security. Following this determination and in response to requests from the U.S. Centers for Disease Control and Prevention, FDA issued letters authorizing the emergency use of certain unapproved and uncleared products or unapproved or uncleared uses of approved or cleared products, provided certain criteria are met, under 21 U.S.C. § 360bbb-3. The marketing and sale of unapproved or uncleared H1N1 Flu Virus-related products that are not authorized by and used in accordance with the conditions of an Emergency Use Authorization, is a potentially significant threat to the public health. Therefore, FDA is taking urgent measures to protect United States consumers from products that, without approval or authorization by FDA, claim to diagnose, mitigate, prevent, treat or cure H1N1 Flu Virus in people.
You should take immediate action to ensure that your firm is not marketing, and does not market
in the future, products intended to diagnose, mitigate, prevent, treat or cure the H1N1 Flu Virus
that have not been approved, cleared, or authorized by the FDA. The above is not meant to be
an all-inclusive list of violations. It is your responsibility to ensure that the products you market
are in compliance with the FFDC Act and FDA's implementing regulations. We advise you to
review your websites, product labels, and other labeling and promotional materials to ensure that
the claims you make for your products do not adulterate or misbrand the products in violation of
the FFDC Act. 21 U.S.C. §§ 331, 351, 352. Within 48 hours, please send an email to
FDAFLUTASKFORCECDER@fda.hhs.gov, describing the actions that you have taken or plan to take to address your firm's violations. If your firm fails to take corrective action immediately, FDA may take enforcement action, such as seizure or injunction for violations of the FFDC Act without further notice. Firms that fail to take corrective action may also be referred to FDA's Office of Criminal Investigations for possible criminal prosecution for violations of the FFDC Act and other federal laws.
FDA is advising consumers not to purchase or use H1N1 Flu Virus-related products offered for sale that have not been approved, cleared, or authorized by FDA. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning marketing unapproved/uncleared, and unauthorized H1N1 Flu Virus-related products in violation of the FFDC Act. This list can be found at www.accessdata.fda.gov/scripts/h1n1flu. Once the violative claims and/or products have been removed from your website, and these corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.
Please note that unapproved, uncleared, or unauthorized products intended to diagnose,
mitigate, prevent, treat, or cure the H1N1 Flu Virus offered for importation into the United States
are subject to detention and refusal of admission. We will advise the appropriate regulatory or
law enforcement officials in the country from which you operate that FDA considers your product
listed above to be an unapproved, uncleared, or unauthorized product that cannot be legally sold
to consumers in the United States.
Please direct any inquiries concerning this letter to FDA at
FDAFLUTASKFORCECDER@fda.hhs.gov or by contacting Andrea Vincent at 301-796-3751.
Deborah M. Autor, Esq.
Office of Compliance
Center for Drug Evaluation and Research